Labcorp expands its diagnostic portfolio by adopting the BD Onclarity HPV Assay, enabling flexible screening options including at-home testing for patients across its extensive US network.
Labcorp is strengthening its diagnostic portfolio by becoming the first commercial laboratory to integrate the FDA-approved BD Onclarity HPV Assay. This expansion covers multiple testing modalities, including clinician-collected and self-collected samples, which is expected to broaden patient access and drive revenue growth across its extensive network.
Labcorp is the first commercial lab to offer the FDA-approved BD Onclarity HPV Assay for both clinician and self-collected samples.
BD is benefiting from the commercial adoption of its Onclarity HPV Assay by Labcorp, a major diagnostic provider. This partnership validates the clinical utility of BD's diagnostic technology and signals a potential increase in recurring revenue through the widespread deployment of their assay across Labcorp's national network.
It marks the commercial adoption of BD's Onclarity HPV Assay, expanding its reach into clinic, patient service center, and at-home testing environments.
Labcorp has become the first commercial laboratory to integrate the FDA-approved BD Onclarity HPV Assay across its testing network. The rollout covers clinician-collected and self-collected samples, spanning clinic, patient service center, and at-home testing environments to broaden diagnostic reach.
The partnership marks the first commercial deployment of the FDA-approved BD Onclarity HPV Assay, allowing for more flexible screening options including self-collection and at-home testing.